Managing risks in biotechnology: can we learn from nuclear power?

Managing risks in biotechnology: can we learn from nuclear power?

The potential of biotechnology to cure disease and feed the Third World has not eased public disquiet about its safety. In the rush to commercialization, can lessons be learnt from the introduction of nuclear power a generation ago? While France's nuclear programme stayed on track, America'...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Foresight (Cambridge) 2001-02, Vol.3 (1), p.33-45
Hauptverfasser: Gaivoronskaia, Galina, Erik Solem, Knut
Format: Artikel
Sprache:eng
Schlagworte:
Biotechnology
Genetic testing
Nuclear industry
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 45
container_issue 1
container_start_page 33
container_title Foresight (Cambridge)
container_volume 3
creator Gaivoronskaia, Galina
Erik Solem, Knut
description The potential of biotechnology to cure disease and feed the Third World has not eased public disquiet about its safety. In the rush to commercialization, can lessons be learnt from the introduction of nuclear power a generation ago? While France's nuclear programme stayed on track, America's was derailed by accidents and corporate secrecy. So is an industry under state control safer than one in private hands? And in the absence of clear evidence about the long-term effects of genetic manipulation, how can we design a consultation process that addresses public concerns?
doi_str_mv 10.1108/14636680110802978
format Article
fullrecord <record><control><sourceid>proquest_istex</sourceid><recordid>TN_cdi_istex_primary_ark_67375_4W2_CBRDRTD6_2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17865274</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-6a429b6f93bb101375ff380aa78d8e56588928f5a463ce330edaff55f10e7dba3</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRSMEEqXwAey8YkVgbCeOzQaVlpcEQqqKWFpOYpfQPIqdqvTvcQkCCVR1NQ-dO3NnguAYwxnGwM9xxChjHNYFEJHwnaDne3EoOCW7XzkNPSD2gwPn3gAIiAR6weBR1Wpa1FNkCzdzqKhRWjStzl7rpmymqwuUqRotNSq1sjUytqlQvcjWFZo3S20vD4M9o0qnj75jP3i-uZ4M78KHp9v74eAhzKjgbchURETKjKBpigHTJDaGclAq4TnXMYs5F4SbWHmjmaYUdK6MiWODQSd5qmg_OOnmzm3zvtCulVXhMl2WqtbNwknKgFCI8HYQhKCY8K0gTjiLSRJ5EHdgZhvnrDZybotK2ZXEINcfl__e7zVhpylcqz9-BMrOJEv89TJ6IXJ4NR6NJyMmiedPO15X2qoy_13xd7Sc58bjsAHf6OgTQmShBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17865274</pqid></control><display><type>article</type><title>Managing risks in biotechnology: can we learn from nuclear power?</title><source>Emerald Journals</source><source>Standard: Emerald eJournal Premier Collection</source><creator>Gaivoronskaia, Galina ; Erik Solem, Knut</creator><creatorcontrib>Gaivoronskaia, Galina ; Erik Solem, Knut</creatorcontrib><description>The potential of biotechnology to cure disease and feed the Third World has not eased public disquiet about its safety. In the rush to commercialization, can lessons be learnt from the introduction of nuclear power a generation ago? While France's nuclear programme stayed on track, America's was derailed by accidents and corporate secrecy. So is an industry under state control safer than one in private hands? And in the absence of clear evidence about the long-term effects of genetic manipulation, how can we design a consultation process that addresses public concerns?</description><identifier>ISSN: 1463-6689</identifier><identifier>EISSN: 1465-9832</identifier><identifier>DOI: 10.1108/14636680110802978</identifier><language>eng</language><publisher>MCB UP Ltd</publisher><subject>Biotechnology ; Genetic testing ; Nuclear industry</subject><ispartof>Foresight (Cambridge), 2001-02, Vol.3 (1), p.33-45</ispartof><rights>MCB UP Limited</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-6a429b6f93bb101375ff380aa78d8e56588928f5a463ce330edaff55f10e7dba3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.emerald.com/insight/content/doi/10.1108/14636680110802978/full/pdf$$EPDF$$P50$$Gemerald$$H</linktopdf><linktohtml>$$Uhttps://www.emerald.com/insight/content/doi/10.1108/14636680110802978/full/html$$EHTML$$P50$$Gemerald$$H</linktohtml><link.rule.ids>314,780,784,967,11635,21695,27924,27925,52686,52689,53244,53372</link.rule.ids></links><search><creatorcontrib>Gaivoronskaia, Galina</creatorcontrib><creatorcontrib>Erik Solem, Knut</creatorcontrib><title>Managing risks in biotechnology: can we learn from nuclear power?</title><title>Foresight (Cambridge)</title><description>The potential of biotechnology to cure disease and feed the Third World has not eased public disquiet about its safety. In the rush to commercialization, can lessons be learnt from the introduction of nuclear power a generation ago? While France's nuclear programme stayed on track, America's was derailed by accidents and corporate secrecy. So is an industry under state control safer than one in private hands? And in the absence of clear evidence about the long-term effects of genetic manipulation, how can we design a consultation process that addresses public concerns?</description><subject>Biotechnology</subject><subject>Genetic testing</subject><subject>Nuclear industry</subject><issn>1463-6689</issn><issn>1465-9832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNqFkMtOwzAQRSMEEqXwAey8YkVgbCeOzQaVlpcEQqqKWFpOYpfQPIqdqvTvcQkCCVR1NQ-dO3NnguAYwxnGwM9xxChjHNYFEJHwnaDne3EoOCW7XzkNPSD2gwPn3gAIiAR6weBR1Wpa1FNkCzdzqKhRWjStzl7rpmymqwuUqRotNSq1sjUytqlQvcjWFZo3S20vD4M9o0qnj75jP3i-uZ4M78KHp9v74eAhzKjgbchURETKjKBpigHTJDaGclAq4TnXMYs5F4SbWHmjmaYUdK6MiWODQSd5qmg_OOnmzm3zvtCulVXhMl2WqtbNwknKgFCI8HYQhKCY8K0gTjiLSRJ5EHdgZhvnrDZybotK2ZXEINcfl__e7zVhpylcqz9-BMrOJEv89TJ6IXJ4NR6NJyMmiedPO15X2qoy_13xd7Sc58bjsAHf6OgTQmShBg</recordid><startdate>20010201</startdate><enddate>20010201</enddate><creator>Gaivoronskaia, Galina</creator><creator>Erik Solem, Knut</creator><general>MCB UP Ltd</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope><scope>7TA</scope><scope>8FD</scope><scope>JG9</scope></search><sort><creationdate>20010201</creationdate><title>Managing risks in biotechnology: can we learn from nuclear power?</title><author>Gaivoronskaia, Galina ; Erik Solem, Knut</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-6a429b6f93bb101375ff380aa78d8e56588928f5a463ce330edaff55f10e7dba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Biotechnology</topic><topic>Genetic testing</topic><topic>Nuclear industry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gaivoronskaia, Galina</creatorcontrib><creatorcontrib>Erik Solem, Knut</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Materials Business File</collection><collection>Technology Research Database</collection><collection>Materials Research Database</collection><jtitle>Foresight (Cambridge)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gaivoronskaia, Galina</au><au>Erik Solem, Knut</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Managing risks in biotechnology: can we learn from nuclear power?</atitle><jtitle>Foresight (Cambridge)</jtitle><date>2001-02-01</date><risdate>2001</risdate><volume>3</volume><issue>1</issue><spage>33</spage><epage>45</epage><pages>33-45</pages><issn>1463-6689</issn><eissn>1465-9832</eissn><abstract>The potential of biotechnology to cure disease and feed the Third World has not eased public disquiet about its safety. In the rush to commercialization, can lessons be learnt from the introduction of nuclear power a generation ago? While France's nuclear programme stayed on track, America's was derailed by accidents and corporate secrecy. So is an industry under state control safer than one in private hands? And in the absence of clear evidence about the long-term effects of genetic manipulation, how can we design a consultation process that addresses public concerns?</abstract><pub>MCB UP Ltd</pub><doi>10.1108/14636680110802978</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1463-6689
ispartof Foresight (Cambridge), 2001-02, Vol.3 (1), p.33-45
issn 1463-6689
1465-9832
language eng
recordid cdi_istex_primary_ark_67375_4W2_CBRDRTD6_2
source Emerald Journals; Standard: Emerald eJournal Premier Collection
subjects Biotechnology
Genetic testing
Nuclear industry
title Managing risks in biotechnology: can we learn from nuclear power?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T02%3A35%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_istex&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Managing%20risks%20in%20biotechnology:%20can%20we%20learn%20from%20nuclear%20power?&rft.jtitle=Foresight%20(Cambridge)&rft.au=Gaivoronskaia,%20Galina&rft.date=2001-02-01&rft.volume=3&rft.issue=1&rft.spage=33&rft.epage=45&rft.pages=33-45&rft.issn=1463-6689&rft.eissn=1465-9832&rft_id=info:doi/10.1108/14636680110802978&rft_dat=%3Cproquest_istex%3E17865274%3C/proquest_istex%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17865274&rft_id=info:pmid/&rfr_iscdi=true